Implications of cell division cycle associated 4 on the Wilm’s tumor cells viability via AKT/mTOR signaling pathway

References

• Friedman AD. Wilms tumor. Pediatr Rev. 2013;34(7):328–330. discussion 330.
   PubMedGoogle Scholar
• Hohenstein P, Pritchard-Jones K, Charlton J. The yin and yang of kidney development and Wilms’ tumors. Genes Dev. 2015;29(5):467–482.
   PubMed Web of Science ®Google Scholar
• Pritchard-Jones K. Controversies and advances in the management of Wilms’ tumour. Arch Dis Child. 2002;87(3):241–244.
   PubMed Web of Science ®Google Scholar
• Cone EB, Dalton SS, Van Noord M, et al. Biomarkers for Wilms tumor: a systematic review. J Urol. 2016;196(5):1530–1535.
   PubMed Web of Science ®Google Scholar
• Phelps HM, Kaviany S, Borinstein SC, et al. Iological drivers of Wilms tumor prognosis and treatment. Children (Basel, Switzerland). 2018;5(11):145.
   Web of Science ®Google Scholar
• Irtan S, Ehrlich PF, Pritchard-Jones K. Wilms tumor: "State-of-the-art" update, 2016. Semin Pediatr Surg. 2016;25(5):250–256.
   PubMed Web of Science ®Google Scholar
• Vader G, Lens SM. The Aurora kinase family in cell division and cancer. Biochim Biophys Acta. 2008;1786(1):60–72.
   PubMed Web of Science ®Google Scholar
• Collins I, Garrett MD. Targeting the cell division cycle in cancer: CDK and cell cycle checkpoint kinase inhibitors. Curr Opin Pharmacol. 2005;5(4):366–373.
   PubMed Web of Science ®Google Scholar
• Altieri DC. Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene. 2003;22(53):8581–8589.
   PubMed Web of Science ®Google Scholar
• Walker MG. Drug target discovery by gene expression analysis: cell cycle genes. Curr Cancer Drug Targets. 2001;1(1):73–83.
   PubMed Web of Science ®Google Scholar
• Hayashi R, Goto Y, Ikeda R, et al. CDCA4 is an E2F transcription factor family-induced nuclear factor that regulates E2F-dependent transcriptional activation and cell proliferation. J Biol Chem. 2006;281(47):35633–35648.
   PubMed Web of Science ®Google Scholar
• Tategu M, Nakagawa H, Hayashi R, et al. Transcriptional co-factor CDCA4 participates in the regulation of JUN oncogene expression. Biochimie. 2008;90(10):1515–1522.
   PubMed Web of Science ®Google Scholar
• Xu Y, Wu X, Li F, et al. CDCA4, a downstream gene of the Nrf2 signaling pathway, regulates cell proliferation and apoptosis in the MCF‑7/ADM human breast cancer cell line. Mol Med Rep. 2018;17(1):1507–1512.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Cheng Y, Zhang Z, et al. CDCA2 inhibits apoptosis and promotes cell proliferation in prostate cancer and is directly regulated by HIF-1α pathway. Front Oncol. 2020;10:725.
   PubMed Web of Science ®Google Scholar
• Zhao XS, Han B, Zhao JX, et al. MiR-155-5p affects Wilms’ tumor cell proliferation and apoptosis via targeting CREB1. Eur Rev Med Pharmacol Sci. 2019;23(3):1030–1037.
   PubMed Web of Science ®Google Scholar
• Compagni A, Christofori G. Recent advances in research on multistage tumorigenesis. Br J Cancer. 2000;83(1):1–5.
   PubMed Web of Science ®Google Scholar
• Sulić S, Panić L, Dikić I, et al. Deregulation of cell growth and malignant transformation. Croat Med J. 2005;46(4):622–638.
   PubMed Web of Science ®Google Scholar
• Qi C, Hu Y, Yang F, et al. Preliminary observations regarding the expression of collagen triple helix repeat-containing 1 is an independent prognostic factor for Wilms’ tumor. J Pediatr Surg. 2016;51(9):1501–1506.
   PubMed Web of Science ®Google Scholar
• Brok J, Pritchard-Jones K, Geller JI, et al. Review of phase I and II trials for Wilms’ tumour - can we optimise the search for novel agents? Eur J Cancer. 2017;79:205–213.
   PubMed Web of Science ®Google Scholar
• Phan NN, Wang CY, Li KL, et al. Distinct expression of CDCA3, CDCA5, and CDCA8 leads to shorter relapse free survival in breast cancer patient. Oncotarget. 2018;9(6):6977–6992.
   PubMedGoogle Scholar
• Chen C, Chen S, Luo M, et al. The role of the CDCA gene family in ovarian cancer. Ann Transl Med. 2020;8(5):190–190.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Shen M, Zhou G. Upregulation of CDCA5 promotes gastric cancer malignant progression via influencing cyclin E1. Biochem Biophys Res Commun. 2018;496(2):482–489.
   PubMed Web of Science ®Google Scholar
• Wang X, Song P, Huang C, et al. Weighted gene co‑expression network analysis for identifying hub genes in association with prognosis in Wilms tumor. Mol Med Rep. 2019;19(3):2041–2050.
   PubMed Web of Science ®Google Scholar
• Pang S, Xu Y, Chen J, et al. Knockdown of cell division cycle-associated protein 4 expression inhibits proliferation of triple negative breast cancer MDA-MB-231 cells in vitro and in vivo. Oncol Lett. 2019;17(5):4393–4400.
   PubMed Web of Science ®Google Scholar
• Alderman C, Yang Y. The anti-melanoma activity and oncogenic targets of hsa-miR-15a-5p. RNA & Dis. 2016;3(4):e1450.
   PubMedGoogle Scholar
• Wu B, Huang Y, Luo Y, et al. The diagnostic and prognostic value of cell division cycle associated gene family in hepatocellular carcinoma. J Cancer. 2020;11(19):5727–5737.
   PubMed Web of Science ®Google Scholar
• Sulaimanov N, Klose M, Busch H, et al. Understanding the mTOR signaling pathway via mathematical modeling. Wiley Interdiscip Rev Syst Biol Med. 2017;9(4):e1379.
   Web of Science ®Google Scholar
• Tian T, Li X, Zhang J. mTOR signaling in cancer and mTOR inhibitors in solid tumor targeting therapy. IJMS. 2019;20(3):755.
   Google Scholar
• Mo C, Shetti D, Wei K. Erianin inhibits proliferation and induces apoptosis of HaCaT cells via ROS-Mediated JNK/c-Jun and AKT/mTOR signaling pathways. Molecules. 2019;24(15):2727.
   Web of Science ®Google Scholar
• Xue H, Li P, Luo Y, et al. Salidroside stimulates the Sirt1/PGC-1α axis and ameliorates diabetic nephropathy in mice. Phytomedicine. 2019;54:240–247.
   PubMed Web of Science ®Google Scholar
• Calvo E, Porta C, Grünwald V, et al. The current and evolving landscape of first-line treatments for advanced renal cell carcinoma. Oncologist. 2019;24(3):338–348.
   PubMed Web of Science ®Google Scholar
• Ong PS, Wang LZ, Dai X, et al. Judicious toggling of mTOR activity to combat insulin resistance and cancer: current evidence and perspectives. Front Pharmacol. 2016;7:395.
   PubMed Web of Science ®Google Scholar
• Formisano L, Napolitano F, Rosa R, et al. Mechanisms of resistance to mTOR inhibitors. Crit Rev Oncol Hematol. 2020;147:102886.
   PubMed Web of Science ®Google Scholar